ALY-301 is a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity  Designed to enable safe dosing in chronic conditions and deliver clinical ...

Abbisko Therapeutics Co., Ltd. (02256.HK) today announced that the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for pimicotinib, ...